2025-09-19 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc. (HIMS) based on the provided data, presented in English with simple numbers and brief insights.

## Hims & Hers Health Inc. (HIMS) - Analysis

**Company Overview:** Hims & Hers Health Inc. is a telehealth company offering personalized health and wellness solutions.

### 1. Performance vs. S&P 500 (VOO)

*   **HIMS Cumulative Return:** 216.73%
*   **VOO Cumulative Return:** 74.59%
*   **Absolute Divergence:** 139.7
*   **Relative Divergence:** 60.5

**Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) over the period covered by the data.  The relative divergence of 60.5 indicates HIMS's performance is positioned towards the higher end of its historical outperformance range.

**Alpha, Beta Analysis:**

| Year        | CAGR     | MDD   | Alpha   | Beta | Cap(B) |
| ----------- | -------- | ----- | ------- | ---- | ------ |
| 2019-2021   | -46.0%   | 51.0% | -84.0%  | -0.0 | 1.5    |
| 2020-2022   | -15.0%   | 72.1% | -17.0%  | -0.0 | 1.4    |
| 2021-2023   | -51.0%   | 72.1% | -69.0%  | -0.1 | 2.0    |
| 2022-2024   | 127.0%  | 78.4% | 101.0%  | -0.1 | 5.5    |
| 2023-2025   | 212.0%  | 80.7% | 154.0%  | -0.1 | 12.7   |

**Analysis:**

*   **CAGR:** The CAGR varies significantly, with negative values in the earlier periods and strong positive values in the more recent periods, indicating a recent surge in growth.
*   **MDD:** The Maximum Drawdown is consistently high, reflecting significant volatility.
*   **Alpha:** The alpha values are mostly negative, indicating underperformance relative to the benchmark. However, the recent periods (2022-2024 and 2023-2025) show strong positive alpha, indicating significant outperformance.
*   **Beta:** The beta values are close to zero, suggesting low systematic risk or correlation with the overall market.
*   **Cap:** The market capitalization has increased significantly, indicating substantial growth in the company's value.

### 2. Recent Stock Price Movement

*   **Current Price:** 56.20
*   **Last Market Data:** price: 56.2, previousClose: 50.35, change: 11.62
*   **5-day Moving Average:** 53.38
*   **20-day Moving Average:** 47.86
*   **60-day Moving Average:** 50.27

**Analysis:** The current price is above all moving averages, suggesting a short-term and medium-term upward trend. The recent significant change (11.62) indicates a strong upward movement.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 69.64
*   **PPO:** 2.19
*   **Hybrid Signal:** Cash_0%_Buy 90%
*   **Recent (20-day) Relative Divergence Change:** +9.7 (Short-term Increase)
*   **Expected Return:** -8.7%

**Analysis:**

*   The MRI indicates a "Low Risk" environment.
*   The RSI is approaching overbought territory (above 70), suggesting the stock may be due for a pullback.
*   The PPO is positive, supporting the upward trend.
*   The hybrid signal suggests a strong buy.
*   The recent increase in relative divergence (+9.7) indicates a strengthening of HIMS's outperformance.
*   The negative expected return suggests a cautious outlook on long-term returns compared to the S&P 500.
*   The significant positive change in the last market data reflects a recent surge, which should be considered in the overall analysis.

### 4. Recent News & Significant Events

*   **FDA Scrutiny:**  Hims & Hers, along with Eli Lilly and Novo Nordisk, face FDA scrutiny related to weight-loss products.
*   **Insider Selling:** A Hims & Hers Health insider sold a substantial amount of shares.
*   **Analyst Target Price Increase:** Argus Research raised the target price to $41.

**Analysis:**

*   The FDA scrutiny could present a regulatory risk.
*   Insider selling might be interpreted negatively by some investors.
*   The analyst target price increase suggests some positive sentiment, but the target is below the current price.

### 4-2. Analyst Opinions

*   **Consensus:** Hold
*   **Mean Rating:** 2.92 (~Hold)
*   **Number of Opinions:** 12
*   **Target Price (avg/high/low):** 47.42 / 85.00 / 25.00

**Analysis:** The analyst consensus is "Hold" with a mean rating suggesting a neutral stance. The average target price is below the current price, indicating potential limited upside according to analysts.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출        |
| -------- | ----- | ----------- |
| 2025-08-04 | 0.19  | 0.54 B$     |
| 2025-05-05 | 0.22  | 0.59 B$     |
| 2024-11-04 | 0.35  | 0.40 B$     |
| 2024-08-05 | 0.06  | 0.32 B$     |
| 2025-08-04 | 0.06  | 0.32 B$     |

**Analysis:**

*   EPS and revenue show a generally increasing trend over the last few quarters.
*   The latest earnings report (2025-08-04) shows a slight decrease in EPS but a significant increase in revenue compared to the same quarter last year.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
| ------------ | -------- | ------------- |
| 2025-06-30   | $0.54B   | 76.39%        |
| 2025-03-31   | $0.59B   | 73.50%        |
| 2024-12-31   | $0.48B   | 76.81%        |
| 2024-09-30   | $0.40B   | 79.16%        |
| 2024-06-30   | $0.32B   | 81.30%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE    |
| ------------ | -------- | ------ |
| 2025-06-30   | $0.56B   | 7.55%  |
| 2025-03-31   | $0.55B   | 9.01%  |
| 2024-12-31   | $0.48B   | 5.46%  |
| 2024-09-30   | $0.44B   | 17.18% |
| 2024-06-30   | $0.36B   | 3.67%  |

**Analysis:**

*   **Revenue:** Revenue is consistently growing quarter over quarter.
*   **Profit Margin:** The profit margin is high but has been slightly decreasing recently.
*   **Equity:** Equity is increasing, indicating growth in the company's net assets.
*   **ROE:** The Return on Equity (ROE) fluctuates, suggesting varying levels of efficiency in generating profit from equity.

### 7. Overall Summary

Hims & Hers Health Inc. (HIMS) has shown significant outperformance compared to the S&P 500. Recent earnings and revenue growth are positive. However, the stock is approaching overbought territory, and the analyst consensus is "Hold" with an average target price below the current level.  The FDA scrutiny and insider selling introduce some risk.  The recent surge in price suggests momentum, but caution is warranted due to the regulatory uncertainties and the relatively high valuation compared to analyst targets.
